Abcentra, LLC is a clinical-stage biopharmaceutical company based in Los Angeles, CA, dedicated to developing innovative therapeutics for cardiovascular and inflammatory diseases. With a focus on patient populations at high risk of accelerated atherosclerosis and cardiovascular events due to chronic inflammation, their pipeline targets oxidized lipoproteins, potent inflammatory mediators implicated in various inflammatory diseases.
Abcentra's clinical and preclinical programs aim to address unmet needs in conditions such as plaque psoriasis, accelerated atherosclerosis, and aortic valve stenosis, offering potential treatments for these inflammatory diseases. Through their research and development efforts, Abcentra strives to provide first-in-class therapies that can significantly improve patient outcomes and quality of life.
Generated from the website